<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231293</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-OS-401</org_study_id>
    <nct_id>NCT03231293</nct_id>
  </id_info>
  <brief_title>Fimasartan Blood Pressure Lowering After Acute Stroke</brief_title>
  <acronym>FABULOUS</acronym>
  <official_title>A Multicenter Longitudinal Observational Study to Assess the Effectiveness of Fimasartan-based Antihypertensive Treatment and Prognosis in Post-Acute Phase of Ischemic Stroke or Transient Ischemic Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and
      prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All
      participants will receive fimasartan, and the investigators will follow them up for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure control rate(&lt;140/90 mmHg)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control rate(&lt;140/90 mmHg)</measure>
    <time_frame>4, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure changes</measure>
    <time_frame>4, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS changes</measure>
    <time_frame>4, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fimasartan-based treatment modalities</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fimasartan starting point after stroke</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke recurrence</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates from cardiovascular disease</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rates of any cause</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to antihypertensive treatments</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1032</enrollment>
  <condition>Hypertension</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <eligibility>
    <study_pop>
      <textblock>
        1,032 subjects of post-acute phase of ischemic stroke or transient ischemic attack patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke or transient ischemic attack occurs after 7 days to 3 months.

          -  Mean blood pressure measured 3 times at the first visit (Visit 1) should be over 140
             mmHg for systolic blood pressure or 90 mmHg for diastolic blood pressure

          -  Suitable for administration of fimasartan

          -  The life expectancy should be over 6 months.

        Exclusion Criteria:

          -  Patients already treated with antihypertensive medications

          -  Hemorrhagic stroke patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sun U Kwon, MD</last_name>
    <phone>02-3010-3440</phone>
    <email>sunkwon7@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo S Nam, MD</last_name>
      <phone>02-2228-1617</phone>
      <email>HSNAM@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

